Log In
Print this Print this

SynCon Zika DNA vaccine (GLS-5700)

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionSynthetic DNA vaccine constructs targeting multiple Zika virus antigens administered using Inovio's Cellectra electroporation technology
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationViral infection
Indication DetailsVaccinate against Zika virus infection
Regulatory Designation
PartnerGeneOne Life Science Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today